Ares Financial Consulting’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
Other funds holding BMRN
Ares Financial Consulting's BMRN Position: Q3 2026 in Review
Ares Financial Consulting held its BioMarin Pharmaceuticals (BMRN) position steady in Q3 2026 at 70 shares worth $4.2K. The position accounts for ﹤0.01% of the portfolio, ranked #737.
Ares Financial Consulting first reported a position in BMRN in Q1 2026 and has held it in 3 quarters since. 567 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.
- Ares Financial Consulting held 70 shares of BioMarin Pharmaceuticals worth $4.2K as of Q3 2026.
- Ares Financial Consulting left its BioMarin Pharmaceuticals share count unchanged in Q3 2026.
- BioMarin Pharmaceuticals made up ﹤0.01% of Ares Financial Consulting's portfolio in Q3 2026, its #737 holding.
- Ares Financial Consulting first reported a position in BioMarin Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
- 567 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.
Based on Ares Financial Consulting's 13F filing for Q3 2026, filed 19 Oct 2026.